2seventy bio (NASDAQ:TSVT) is a clinical-stage biotechnology company focused on the discovery, development and manufacturing of engineered cell therapies for the treatment of cancer. The company’s proprietary platforms leverage both autologous and allogeneic approaches to address solid tumors and hematologic malignancies. Through a multi-modality pipeline, 2seventy bio aims to expand the reach of cell-based immunotherapies beyond current indications, harnessing T cell receptors (TCRs), chimeric antigen receptors (CARs) and natural killer (NK) cells.
The company’s lead programs include TCR-T cell candidates targeting well-characterized tumor antigens such as NY-ESO-1 and MAGE-A4, as well as next-generation CAR-T constructs designed to overcome tumor microenvironment barriers. In parallel, 2seventy bio is developing off-the-shelf NK cell therapies engineered for enhanced persistence and cytotoxicity. Its integrated manufacturing network supports both clinical supply and scalable commercial production, enabling efficient translation from discovery to late-stage trials.
2seventy bio was formed through a business combination in 2022 and is headquartered in Cambridge, Massachusetts, with additional research and development facilities in Seattle and Europe. The company maintains active clinical trial programs across North America, Asia and Europe, collaborating with leading academic centers and oncology consortia. This global footprint aims to accelerate patient access to innovative cell therapy candidates and generate robust clinical data in diverse patient populations.
Under the leadership of President and CEO Charles J. Wilson, Ph.D., 2seventy bio leverages decades of experience in cell therapy research and development. The executive team includes seasoned industry veterans in manufacturing, regulatory affairs and clinical development, fostering strategic partnerships with pharmaceutical companies and academic institutions. Together, they are committed to advancing next-generation cell therapies that address unmet medical needs in oncology.
